Pharmacokinetic Similarity of ABP 654, an Ustekinumab Biosimilar Candidate: Results from a Randomized, Double‐blind Study in Healthy Subjects

• Published in: Clinical pharmacology in drug development Vol. 12; no. 9; pp. 863 - 873
• Main Authors: Chow, Vincent, Mytych, Daniel T., Das, Shyamal, Franklin, Janet
• Format: Journal Article
• Language: English
• Published: United States Wiley Subscription Services, Inc 01.09.2023
• Subjects: ABP 654; Biological products; biosimilar; Cytokines; Double-blind studies; Monoclonal antibodies; Pharmacokinetics; ustekinumab; United States > US; pharmacokinetics; ustekinumab; ABP 654; biosimilar

ABP 654 is a proposed biosimilar to ustekinumab reference product (RP) which works through antagonism of interleukin‐12 and interleukin‐23. Ustekinumab RP is used for the treatment of chronic inflammatory conditions, including some forms of plaque psoriasis, psoriatic arthritis, Crohn's disease...